Logo image of ONCS

OncoSec Medical Incorporated (ONCS) Stock Fundamental Analysis

NASDAQ:ONCS - Nasdaq - US68234L4059 - Common Stock - Currency: USD

0.2772  +0.07 (+31.87%)

After market: 0.23 -0.05 (-17.03%)

Fundamental Rating

0

Taking everything into account, ONCS scores 0 out of 10 in our fundamental rating. ONCS was compared to 549 industry peers in the Biotechnology industry. ONCS has a bad profitability rating. Also its financial health evaluation is rather negative. ONCS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONCS had negative earnings in the past year.
In the past year ONCS has reported a negative cash flow from operations.
In the past 5 years ONCS always reported negative net income.
In the past 5 years ONCS always reported negative operating cash flow.
ONCS Yearly Net Income VS EBIT VS OCF VS FCFONCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for ONCS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONCS Yearly ROA, ROE, ROICONCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCS Yearly Profit, Operating, Gross MarginsONCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

ONCS has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ONCS has a worse debt to assets ratio.
ONCS Yearly Shares OutstandingONCS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
ONCS Yearly Total Debt VS Total AssetsONCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -59.67, we must say that ONCS is in the distress zone and has some risk of bankruptcy.
ONCS has a Altman-Z score of -59.67. This is amonst the worse of the industry: ONCS underperforms 92.77% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.67
ROIC/WACCN/A
WACCN/A
ONCS Yearly LT Debt VS Equity VS FCFONCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.89 indicates that ONCS may have some problems paying its short term obligations.
The Current ratio of ONCS (0.89) is worse than 88.91% of its industry peers.
ONCS has a Quick Ratio of 0.89. This is a bad value and indicates that ONCS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.89, ONCS is doing worse than 87.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
ONCS Yearly Current Assets VS Current LiabilitesONCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.16% over the past year.
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCS Yearly EPS VS EstimatesONCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCS. In the last year negative earnings were reported.
Also next year ONCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCS Price Earnings VS Forward Price EarningsONCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCS Per share dataONCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OncoSec Medical Incorporated

NASDAQ:ONCS (6/23/2023, 8:00:02 PM)

After market: 0.23 -0.05 (-17.03%)

0.2772

+0.07 (+31.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-15 2023-06-15/amc
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners49.44%
Ins Owner Change0%
Market Cap1.65M
Analysts43.33
Price Target5.1 (1739.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.96%
Min EPS beat(2)9.96%
Max EPS beat(2)9.96%
EPS beat(4)3
Avg EPS beat(4)12.34%
Min EPS beat(4)9.96%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.14
EYN/A
EPS(NY)-2.42
Fwd EYN/A
FCF(TTM)-4.19
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0
BVpS-0.92
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.89
Altman-Z -59.67
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.52%
OCF growth 3YN/A
OCF growth 5YN/A